Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Treatment Option For Managing Anaemia Could Improve Quality Of Life For People With Severe Kidney Disease

19.10.2007
The use of an anti-anaemia drug as infrequently as once a month to boost haemoglobin concentrations among people with severe kidney disease could result in improved quality of life and simplified anaemia management compared with conventional therapy for treating anaemia, conclude authors of a study in this week’s issue of The Lancet.

Conventional treatment with epoetin (a synthetic form of human erythropoietin that promotes red-blood cell production) to manage anaemia in chronic kidney disease needs frequent administrations (at least weekly), changes of dose, and close monitoring of haemoglobin concentrations.

Dr Nathan Levin, Renal Research Institute, New York, USA, and colleagues compared the effectiveness of a long-acting erythropoieses-stimulating agent variant of epoetin (methoxy polyethylene glycol-epoetin beta), given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week for haemoglobin control in haemodialysis patients. The study was designed so that all patients (673 in total, from North America and Europe) received conventional epoetin treatment initially; after four weeks a third of individuals were given methoxy polyethylene glycol-epoetin beta every two weeks, another third given methoxy polyethylene glycol-epoetin beta every four weeks, with the remaining third continuing to receive conventional epoetin treatment throughout the trial..

Haemoglobin concentrations were recorded at baseline, throughout the study, and at a final assessment which took place around a mean of 42 weeks after baseline. The main result of the study showed how individuals given methoxy polyethylene glycol-epoetin beta either fortnightly or every four weeks had no statistically significant change in haemoglobin concentrations compared with those who remained on mainly a three-times-a-week regimen of epoetin treatment throughout the study. Adverse outcomes were minimal and similar between the epoetin and methoxy polyethylene glycol-epoetin beta treatment arms.

Dr Levin comments: “Errors with medication occur at an unacceptably high rate of 45%. Extrapolation to about 246000 haemodialysis patients in the USA suggests that 111000 dose errors could happen every month. Treatment with methoxy poly-ethylene glycol-epoetin beta every 4 weeks would need only 13 doses per year, compared with 52–156 doses with conventional epoetin, and would therefore allow fewer opportunities for error. Since our findings show that haemoglobin can be controlled in all dialysis patients with methoxy polyethylene glycol-epoetin beta given every 4 weeks, we advise that this drug should be introduced as an option to epoetin for simplified anaemia management.”

In an accompanying Comment, Dr Rowan Walker, Royal Melbourne Hospital and Monash University Alfred Hospital, Melbourne, Australia, and Dr Giovanni Strippoli, University of Sydney, Australia, and Mario Negri Sud Consortium, Chieti, Italy, say: “Before we can concur on a precise clinical role for this molecule, we need to explore issues other than simply the non-inferiority with other epoetins to reach certain unvalidated surrogates. Different does and molecular characteristics of epoetins may affect patient-level endpoints, independent of achieved haemoglobin. When these issues are examined, we might be truly confident that a newer molecule is non-inferior to existing ones.”

Tony Kirby | alfa
Further information:
http://multimedia.thelancet.com/pdf/press/Dialysis.pdf

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>